Logo 1 Logo 2

Investigational Drug Details

Drug ID: D063
Drug Name: Nevirapine
Synonyms:
Type: small molecule
DrugBank ID: DB00238
DrugBank Description: A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem] Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
PubChem ID: 4463
CasNo: 129618-40-2
Repositioning for NAFLD: Yes
SMILES: CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
Structure:
InChiKey: NQDJXKOVJZTUJA-UHFFFAOYSA-N
Molecular Weight: 266.2979
DrugBank Targets: Reverse transcriptase/RNaseH
DrugBank MoA: Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.
DrugBank Pharmacology: Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.
DrugBank Indication: For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: